Le Lézard
Classified in: Business
Subject: ATY

WeissLaw LLP Reminds GLIBA and CBMG Shareholders About Its Ongoing Investigations


NEW YORK, Sept. 22, 2020 /PRNewswire/ --

If you own shares in any of the companies listed above and
would like to discuss our investigations or have any questions concerning
this notice or your rights or interests, please contact:

Joshua Rubin, Esq.
WeissLaw LLP
1500 Broadway, 16th Floor
New York, NY  10036
(212) 682-3025
(888) 593-4771
[email protected]

GCI Liberty, Inc. (NASDAQ: GLIBA)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of GCI Liberty, Inc. (NASDAQ: GLIBA) in connection with the proposed acquisition of the company by Liberty Broadband.  Under the terms of the transaction, Series A GLIBA shareholders will receive 0.580 shares of Liberty Broadband's Series C common stock for each share of GLIBA stock they hold.  If you own GLIBA shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: http://www.weisslawllp.com/gci-liberty-inc/   

Cellular Biomedicine Group, Inc. (NASDAQ: CBMG)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) in connection with the proposed interested-party acquisition of the company by a newly-formed entity consisting of CBMG's CEO Tony Liu, certain member of the company's management, and a consortium of stockholders and equity investors (the "Affiliates").  Under the terms of the acquisition agreement, CBMG shareholders will receive $19.75 in cash for each share they own.  Notably, the Affiliates consist of company insiders and other large stockholders that collectively hold approximately 51.5% of the outstanding CBMG shares and may have exerted undue influence on the board. If you own CBMG shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: http://www.weisslawllp.com/cellular-biomedicine-group-inc/

SOURCE WeissLaw LLP


These press releases may also interest you

at 21:22
Wall Financial Corporation (the "Company") released its operating results and financial statements for the three months and year  ended January 31, 2024.  The Company recorded net earnings and comprehensive income attributable to shareholders of the...

at 20:40
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...

at 20:39
Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New...

at 20:15
The partnership was unveiled internally at the Franchisor's annual convention in Las Vegas, NV in December 2023, eliciting...

at 19:35
Regenx Tech Corp., (the "Company" or "Regenx") is providing this bi-weekly update on the status of the application to the Alberta Securities Commission for a management cease trade order, under National Policy 12-203 -?? Management Cease Trade...

at 19:14
Kadestone Capital Corp. ("Kadestone" or the "Company") , a vertically integrated property company today announced its financial results for the year ended December 31, 2023....



News published on and distributed by: